Reata Sells Asian Rights to CKD Drug, But Plans To Remain A Solo Act In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately-held Texas biotech gets $35 million upfront from Kyowa Hakko Kirin and sets its sights on a 2011 NDA filing in the U.S.
You may also be interested in...
With Generous Partner Abbott Back For More, Reata Aims High Again
Texas biotech Reata can add another $400 million license deal, its second with Abbott, to the $178 million it has raised from venture backers. But this time it's for preclinical assets.
Reata Sets Sights On 2012 Bardoxolone Launch With $78 Million Financing In Hand
Funding will allow Reata to complete the second of two pivotal trials for its lead product candidate in development for advanced chronic kidney disease.
Reata Sets Sights On 2012 Bardoxolone Launch With $78 Million Financing In Hand
Funding will allow Reata to complete the second of two pivotal trials for its lead product candidate in development for advanced chronic kidney disease.